{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:00:31Z","timestamp":1768770031639,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17km0105002"],"award-info":[{"award-number":["JP17km0105002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.bcp.2018.09.010","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T00:09:34Z","timestamp":1536365374000},"page":"420-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation"],"prefix":"10.1016","volume":"156","author":[{"given":"Takashi","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn Marie Guti\u00e9rrez","family":"Rico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Hishinuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kumondai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Saigusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Nagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Minegishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nariyasu","family":"Mano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyasu","family":"Hirasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bcp.2018.09.010_b0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1515\/dmdi-2012-0027","article-title":"Cytochrome P450 2B6: function, genetics, and clinical relevance","volume":"27","author":"Turpeinen","year":"2012","journal-title":"Drug Metab. Drug Interact."},{"issue":"1","key":"10.1016\/j.bcp.2018.09.010_b0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2018.09.010_b0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fgene.2013.00024","article-title":"Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance","volume":"4","author":"Zanger","year":"2013","journal-title":"Front. Genet."},{"issue":"3","key":"10.1016\/j.bcp.2018.09.010_b0020","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","article-title":"Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression","volume":"307","author":"Lamba","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2018.09.010_b0025","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2004.05.116","article-title":"Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens","volume":"319","author":"Tsuchiya","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.bcp.2018.09.010_b0030","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2217\/pgs.13.111","article-title":"Impact of pharmacogenetics on CNS side effects related to efavirenz","volume":"14","author":"S\u00e1nchez Mart\u00edn","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"12","key":"10.1016\/j.bcp.2018.09.010_b0035","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/phar.1852","article-title":"Role of cytochrome P450 2B6 pharmacogenomics in determining efavirenz-mediated central nervous system toxicity, treatment outcomes, and dosage adjustments in patients with human immunodeficiency virus infection","volume":"36","author":"Vo","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.bcp.2018.09.010_b0040","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1369-1600.2011.00349.x","article-title":"CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction","volume":"18","author":"Levran","year":"2013","journal-title":"Addict. Biol."},{"issue":"5","key":"10.1016\/j.bcp.2018.09.010_b0045","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bbmt.2015.02.001","article-title":"Cytochrome P450 2B6*5 increases relapse after cyclophosphamide-containing conditioning and autologous transplantation for lymphoma","volume":"21","author":"Bachanova","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"4","key":"10.1016\/j.bcp.2018.09.010_b0050","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1124\/dmd.31.4.398","article-title":"Functional characterization of cytochrome P450 2B6 allelic variants","volume":"31","author":"Jinno","year":"2003","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.bcp.2018.09.010_b0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/humu.22295","article-title":"Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools","volume":"34","author":"Radloff","year":"2013","journal-title":"Hum. Mutat."},{"issue":"7","key":"10.1016\/j.bcp.2018.09.010_b0060","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FPC.0b013e32833bba0e","article-title":"Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2\u2013CYP2B6.28, except CYP2B6.22)","volume":"20","author":"Watanabe","year":"2010","journal-title":"Pharmacogenet.Genomics"},{"issue":"10","key":"10.1016\/j.bcp.2018.09.010_b0065","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1124\/dmd.111.040352","article-title":"Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether","volume":"39","author":"Honda","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2018.09.010_b0070","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1038\/ncomms9018","article-title":"Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals","volume":"6","author":"Nagasaki","year":"2015","journal-title":"Nat. commun."},{"issue":"1","key":"10.1016\/j.bcp.2018.09.010_b0075","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2018.09.010_b0080","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/14622416.8.6.547","article-title":"Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro","volume":"8","author":"Desta","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"8","key":"10.1016\/j.bcp.2018.09.010_b0085","first-page":"985","article-title":"Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation","volume":"25","author":"Code","year":"1997","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.bcp.2018.09.010_b0090","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1124\/dmd.118.081737","article-title":"Functional characterization of 21 allelic variants of dihydropyrimidine dehydrogenase identified in 1070 Japanese individuals","volume":"46","author":"Hishinuma","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2018.09.010_b0095","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/S0021-9258(20)82244-3","article-title":"The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature","volume":"239","author":"Omura","year":"1964","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2018.09.010_b0100","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nprot.2009.121","article-title":"Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase","volume":"4","author":"Guengerich","year":"2009","journal-title":"Nat. Protoc."},{"issue":"5","key":"10.1016\/j.bcp.2018.09.010_b0105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/00032719.2012.738343","article-title":"Microplate assay measurement of small amount of P450","volume":"46","author":"Kaneko","year":"2013","journal-title":"Anal. Lett."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2018.09.010_b0110","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0378-4347(97)00650-6","article-title":"High-performance liquid chromatographic method for measurement of cytochrome P450-mediated metabolism of 7-ethoxy-4-trifluoromethylcoumarin","volume":"708","author":"Morse","year":"1998","journal-title":"J. Chromatogr. B: Biomed. Sci. Appl."},{"issue":"4","key":"10.1016\/j.bcp.2018.09.010_b0115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1124\/mol.109.062570","article-title":"Crystalstructure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-\u00c5 resolution","volume":"77","author":"Gay","year":"2010","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2018.09.010_b0120","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/oxfordjournals.jbchem.a124232","article-title":"Importance of the proline-rich region following signal-anchor sequence in the formation of correct conformation of microsomal cytochrome P-450s","volume":"114","author":"Yamazaki","year":"1993","journal-title":"J. Biochem."},{"issue":"5","key":"10.1016\/j.bcp.2018.09.010_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096789","article-title":"Evaluation of influence of single nucleotide polymorphisms in cytochrome P450 2B6 on substrate recognition using computational docking and molecular dynamics simulation","volume":"9","author":"Kobayashi","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2018.09.010_b0130","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1124\/jpet.104.068973","article-title":"Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles","volume":"311","author":"Lang","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2018.09.010_b0135","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/jpet.111.183111","article-title":"Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4\u2013CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex","volume":"338","author":"Zhang","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.bcp.2018.09.010_b0140","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1124\/dmd.111.042176","article-title":"Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene","volume":"39","author":"Lin","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.bcp.2018.09.010_b0145","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","article-title":"Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver","volume":"325","author":"Hofmann","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:03:57Z","timestamp":1757768637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218303927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":29,"alternative-id":["S0006295218303927"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.09.010","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}